Skip to content

3G Transducer 101

by Mriaudio 2 variants

3G Transducer 101 is a Class II device made by Mriaudio, cleared under FDA 510(k) K180100 on 14 Jun 2018 and listed in FDA GUDID since 6 Mar 2026 (UDI-DI B6691010), active as of 23 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 23 Oct 2026

Documents

510(k) K180100

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing NumberB6691010 UDI-DI Date6 Mar 2026ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Traditional NumberK180100 Date14 Jun 2018DecidedStatusActive

Official records

Across registries

2 registries list this device

  • FDA 510(k) K180100 decided 14 Jun 2018 Active
  • FDA GUDID UDI-DI B6691010 listed 6 Mar 2026 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K180100
  2. Listed FDA GUDID B6691010

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
3G Transducer
Generic name
Patient audiovisual communication/entertainment system
Model / Ref / Catalog
101
Primary DI / UDI-DI
B6691010
510(k) Number
FDA product code
LNH
GMDN term
Patient audiovisual communication/entertainment system
Device class
Class II
Regulation number
892.1000
GUDID distribution status
In Commercial Distribution
MRI safety
MR Conditional

Similar devices

Other devices filed under FDA product code LNH (System, Nuclear Magnetic Resonance Imaging).

Other devices from Mriaudio

  • MRIaudioPREM1003

    Class II
  • MRIaudioPREM1004

    Class II
  • MRIaudioPREM1004 1005

    Class II
  • MRIaudio 1507

    Class II

See all devices from Mriaudio →

Properties

  • Lot / batch number
Other properties (14, all answered No)